Cidara Therapeutics, INC

Cidara Therapeutics, Inc. has completed its merger with Merck Sharp & Dohme LLC, becoming a wholly-owned subsidiary.

Merck will acquire Cidara Therapeutics for $221.50 per common share, totaling approximately $9.2 billion, to expand its respiratory portfolio with late-phase antiviral agent CD388.

Cidara Therapeutics reported its third quarter 2025 financial results and provided a corporate update, highlighting an expanded and accelerated Phase 3 plan for its influenza preventative therapeutic, CD388.

Cidara Therapeutics entered a BARDA agreement for up to $339.2 million to advance manufacturing and clinical development of its non-vaccine influenza preventative therapeutic, CD388.

Cidara Therapeutics announced an accelerated and expanded Phase 3 trial for its influenza prophylactic CD388, significantly increasing the potential patient population.

Cidara Therapeutics announced positive Phase 2b trial results for its influenza preventative CD388, significantly strengthening its balance sheet with a $402.5 million public offering.

Cidara Therapeutics reports positive Phase 2b results for its lead influenza drug CD388, secures up to $339.2 million in BARDA funding, and initiates a Phase 3 trial, bolstering its financial runway despite continued net losses.

Cidara Therapeutics announced positive topline results from its Phase 2b NAVIGATE study for CD388, its influenza antiviral candidate, and reported a significantly strengthened cash position.

Cidara Therapeutics reports a net loss for Q1 2025, shifting its focus to the development of CD388 for influenza prophylaxis.

Cidara Therapeutics reacquired full rights to its influenza drug candidate CD388 and divested its commercial product Rezafungin to focus on its Cloudbreak platform.

Cidara Therapeutics reacquired global rights to CD388, its influenza drug candidate, and secured $240 million in a private placement to fund its development.

Cidara Therapeutics divested its rezafungin assets, reacquired CD388, and reported a net loss of $10.3 million for the first quarter of 2024, while shifting focus to its Cloudbreak platform.

Cidara Therapeutics focuses on CD388 development after divesting rezafungin, reporting a net loss of $169.8 million for fiscal year 2024.

Cidara Therapeutics has filed its annual 10-K report, highlighting the commercial launch of REZZAYO, advancements in its Cloudbreak platform, and ongoing clinical trials.

RA Capital Management, L.P. and its affiliates reported the disposition of all their holdings in Cidara Therapeutics, Inc. following its acquisition by Merck.

Cidara Therapeutics director Joshua Resnick's stock options were converted to cash following the company's acquisition by Merck Sharp & Dohme LLC.

Cidara Therapeutics, Inc. completed its merger with a Merck subsidiary, converting all outstanding stock options into cash at $221.50 per common share.

Director James Merson's stock options in Cidara Therapeutics were converted to cash following the company's acquisition by Merck on January 7, 2026.

Cidara Therapeutics director Carin Canale-Theakston's stock options were converted to cash following the company's acquisition by Merck Sharp & Dohme LLC.

Cidara Therapeutics director Bonnie L. Bassler reports disposition of shares and options following the company's acquisition by Merck Sharp & Dohme LLC for $221.50 per common share.

Cidara Therapeutics has filed a definitive proxy statement related to its upcoming shareholder meeting.

Cidara Therapeutics is asking stockholders to vote on proposals including increasing authorized common stock and amending the 2024 Equity Incentive Plan at its upcoming annual meeting.

Cidara Therapeutics has filed a definitive proxy statement related to its upcoming shareholder meeting.

Cidara Therapeutics is asking stockholders to vote on several proposals at its annual meeting, including director elections, increasing authorized common stock, and approving a new equity incentive plan.

Cidara Therapeutics is asking stockholders to approve a reverse stock split and a reduction in authorized shares to meet Nasdaq's minimum bid price requirement and increase flexibility for future financing.

Cidara Therapeutics is registering the resale of 7,041,309 shares of its common stock by selling stockholders after a recent private placement.

Cidara Therapeutics is registering for resale up to 16.8 million shares of its common stock by selling stockholders following a private placement of Series A Preferred Stock.

RA Capital Management reports the completion of the tender offer and merger of Cidara Therapeutics, resulting in its delisting from Nasdaq and RA Capital's full divestment.

Merck Sharp & Dohme LLC's subsidiary, Caymus Purchaser, Inc., will launch a cash tender offer to acquire Cidara Therapeutics, Inc. for $221.50 per common share and $15,505.00 per Series A preferred share.

RA Capital Management and its affiliates reported a dilution of their beneficial ownership in Cidara Therapeutics, Inc. to 10.7% due to new share issuances by the company.

RA Capital Management and its affiliates report a 13.3% beneficial ownership in Cidara Therapeutics, Inc., holding over 3.3 million common shares.

RA Capital Management and its affiliates have significantly increased their beneficial ownership in Cidara Therapeutics, Inc. to 15.8% of outstanding common stock after investing nearly $100 million in a recent public offering.

Vivo Opportunity entities report zero beneficial ownership in Cidara Therapeutics, Inc. following the completion of a merger on January 7, 2026.

The Vanguard Group has reported a 6.38% beneficial ownership stake in Cidara Therapeutics Inc., holding over 2 million shares of common stock.

Commodore Capital LP and its affiliates have reported a 2.0% beneficial ownership stake in Cidara Therapeutics, Inc., totaling 585,000 shares of common stock.

Paradigm BioCapital Advisors LP and related entities have reported a 3.3% beneficial ownership stake in Cidara Therapeutics, Inc. as of September 30, 2025.

BCLS Fund III Investments, LP, an affiliate of Bain Capital, has reported a 9.99% beneficial ownership stake in Cidara Therapeutics, Inc. as of September 30, 2025.

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have filed an amended Schedule 13G, reporting zero beneficial ownership in Cidara Therapeutics, Inc. common stock.